Long intergenic non-protein coding RNA 1503 (LINC01503)

Long intergenic non-protein coding RNA 1503 (LINC01503) is a long non-coding RNA predominantly located on human chromosome 9 (9q34.11) and recognized for its oncogenic role in various cancers[3][4][6][8]. LINC01503 is overexpressed in malignancies such as hepatocellular carcinoma, nasopharyngeal carcinoma, colorectal cancer, and others, where it promotes tumor cell proliferation, migration, invasion, and inhibits apoptosis[2][3][4][6]. Mechanistically, LINC01503 functions by sponging tumor-suppressive microRNAs (e.g., miR-4492, miR-335-5p)[2][5], recruiting chromatin-modifying proteins (e.g., SFPQ, LSD1, EZH2) to activate transcription of oncogenic targets like FOSL1[3][4], and engaging cancer-associated signaling pathways such as MAPK/ERK[4][6]. Its elevated expression in tumors correlates with poor prognosis, advanced stages, and increased metastatic potential, making it a candidate for use as a prognostic biomarker and a potential (though still experimental) therapeutic target[4][6]. No direct drug interactions are known, and therapeutic strategies would likely focus on antisense oligonucleotides or RNA-targeted interventions.

Other names

lnc-PPP2R4-5RP11-65J3.1hCG2021613

Acts as a competitive endogenous RNA (ceRNA), sponging tumor-suppressive microRNAs (e.g., miR-4492, miR-335-5p); Recruits chromatin-modifying proteins (e.g., SFPQ, LSD1, EZH2) to regulate transcription of oncogenes; Activates signaling pathways (e.g., MAPK/ERK).